Happening today at Piper Sandler

Boston from above

At #ACR25? Join Marisa Peluso as she presents the latest preclinical data on the potential of MRT-6160, a VAV1-directed molecular glue degrader, to treat immune-mediated diseases.

Read the full press release here: bit.ly/4o7koyf

Panel A: A graph of investigator-assessed disease-free survival among all patients with ctDNA-positive status who underwent randomization (primary end point). Panel B: A graph of overall survival in the same population (secondary end point).

In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results: nej.md/3WIRtEg

#ESMO25

Tohle je naprostý děs, který překonal všechna očekávání. Pokud je to pravda a jsme alespoň trochu civilizovaná země, tak ministrem být nemůže.

This week’s announcement of a second collaboration with @novartis.bsky.social includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs.

CEO Markus Warmuth comments: bit.ly/3Vl0yTg

At @monterosatx.com, our goal is to bring groundbreaking new therapies to patients. It’s exhilarating to build on our existing collaboration with @novartis.bsky.social in the area of immune-mediated diseases with this second collaboration agreement.

As part of this year’s Dana-Farber TPD Webinar series, Georg Petzold will present on how we’ve upended the paradigm of what is possible with cereblon-based molecular glue degraders. We hope you can join! www.danafarbertargetedproteindegradation.org

At this year’s 2025 Stifel I&I Forum, our CEO, Markus Warmuth, will participate in a fireside chat and provide an overview of our I&I pipeline progress. Learn more: bit.ly/41PXdiR

Today, we published new discoveries in @science.org that
enable development of the next generation of molecular glue degrader (MGD) medicines and substantially expand potential targets addressable with MGDs and our QuEEN™ discovery engine

With the current temperatures it is hard to believe that I skied in New Hampshire in Mt. Washington #backcountry #slackcountry not even 4 weeks ago

Super interesting and exciting data released in @nejm.org. I am bit bothered by two deaths among 14 patients (age range 24-60) in post study period although they do not appear clearly related and happened 19.5 and 30 months post dosing, respectively. #ADA25 #medsky

Takových nás je víc, kteří litují

Drug Discovery in Czechia You have not visited any articles yet, Please visit some articles to see contents here.

One of my colleagues pointed me at this editorial in #JournalofMedicinalChemistry. Medicinal chemistry in my birth country brought some of the best drugs to patients worldwide #medsky #tenofovir pubs.acs.org/doi/full/10....

Začínáme být dost nevoňavý fašistický mess. Dost smutné

Peaceful Protests in Sudbury, Mass (zip code 01776) #NoKings #NoOligarchs #ResistFascism #WeThePeople

Please join us as our CEO Markus Warmuth participates in a fireside chat today at the Jefferies Global Healthcare Conference in New York, sharing insight into our recent progress and strategic priorities: bit.ly/4jDbrtt

#JefferiesHealthcare

Pleased to announce FDA clearance of our IND application for MRT-8102, a NEK7-directed molecular glue degrader designed to target inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6.

Learn more: bit.ly/3FS1Roz

Timely presentation at the #EULAR25 conference around the time we announced the US FDA IND clearance for our NEK7 targeting MGD, MRT-8102

Slackfest still going strong on Mt. Washington snowfields #backcountry #skiing

Are we great yet or is it still yet to come? #taco #tariffssuck

Vermont City Marathon, US state #31, is in the books with yet another BQ finish #VCM25 #RunVermont #50StatesMarathonClub

An Evidence-Based Approach to Covid-19 Vaccination | NEJM This article from the FDA compares broad U.S. recommendations on Covid vaccination with those from other countries and announces the adoption of an evidence-based approach to such recommendations.

@fda.gov new position on COVID booster shots summarized in @nejm.org #medsky www.nejm.org/doi/full/10....

Targeting the NLRP3 inflammasome for inflammatory disease therapy The NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome is a megadalton complex implicated in numerous inflammation-driven diseases including COVID-19, Alzheimer's disease, and gout. Although past efforts have focused on inhibiting IL-1β downstream of NLRP3 activation using drugs such as canakinumab, no FDA-approved NLRP3-targeted inhibitors are currently available. MCC950, a direct NLRP3 inhibitor, showed promise but exhibited off-target effects. Recent research has focused on optimizing the sulfonylurea-based MCC950 scaffold by leveraging recent structural and medicinal chemistry insights into the NLRP3 nucleotide-binding and oligomerization (NACHT) domain to improve solubility and clinical efficacy. In addition, oxidized DNA (oxDNA) has emerged as a key inflammasome trigger, and molecules targeting the pyrin domain have shown promise in inhibiting NLRP3 activation. This review discusses the role of NLRP3 in inflammation-related diseases, the status of ongoing clinical trials, and emerging small-molecule therapeutics targeting NLRP3.

Targeting the NLRP3 inflammasome for inflammatory disease therapy

I made it to #45 (October to May) and even that makes me feel guilty 🤣

20 happiest countries in the world in 2024 according to @worldhappiness.report

👉 14 countries are high income democracies from Northern, Northwestern or Central Europe
👉 USA is the only North American country not making the cut
👉 Israel is the only Asian country on the list

Tuckerman was still going strong on the Mother’s Day weekend #backcountry #skiing

The least-squares mean percent changes in body weight

Presented at #ECO2025:

In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results: nej.md/44ZeMPz

@easoobesity.bsky.social

Vinay Prasad tapped to run FDA center that regulates vaccines, gene therapies Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was forced out.

Not the news I was hoping for…

www.statnews.com/2025/05/06/v...

Routine Surveillance for Cancer Metastases — Does It Help or Harm Patients? | NEJM Research generally suggests that routine surveillance after cancer treatment finds more recurrences — leading to more surgery, chemotherapy, and radiation — without affecting the risk of death.

This perspective on routine surveillance in cancer in @nejm.org resonates with me. Here are key takeaway points:
👉 No mortality benefit
👉 Lead-time bias risk
👉 Potential harms such as financial, “scanxiety” etc.
👉 Questionable impact on management
👉 Less is More
www.nejm.org/doi/pdf/10.1...